Evidence map›Paper›PMID 37257253›Full record

ArticleVirology2023

Activation of p53-regulated pro-survival signals and hypoxia-independent mitochondrial targeting of TIGAR by human papillomavirus E6 oncoproteins.

Lacin Yapindi, Tetiana Bowley, Nick Kurtaneck, Rachel L Bergeson, Kylie James, Jillian Wilbourne, Carolyn K Harrod, Brenda Y Hernandez, Brooke M Emerling, Courtney Yates and 1 more

Open access · greenAbstract read
In one paragraph

Article in Virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Advancements inMolecules (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Lacin YapindiLaboratory of Molecular Virology, Department of Biological Sciences and the Dedman College Center for Drug Discovery, Design & Delivery, Southern Methodist University, Dallas, TX, 75275-0376, United States.
Tetiana BowleyLaboratory of Molecular Virology, Department of Biological Sciences and the Dedman College Center for Drug Discovery, Design & Delivery, Southern Methodist University, Dallas, TX, 75275-0376, United States.
Nick KurtaneckLaboratory of Molecular Virology, Department of Biological Sciences and the Dedman College Center for Drug Discovery, Design & Delivery, Southern Methodist University, Dallas, TX, 75275-0376, United States.
Rachel L BergesonLaboratory of Molecular Virology, Department of Biological Sciences and the Dedman College Center for Drug Discovery, Design & Delivery, Southern Methodist University, Dallas, TX, 75275-0376, United States.
Kylie JamesLaboratory of Molecular Virology, Department of Biological Sciences and the Dedman College Center for Drug Discovery, Design & Delivery, Southern Methodist University, Dallas, TX, 75275-0376, United States.
Jillian WilbourneLaboratory of Molecular Virology, Department of Biological Sciences and the Dedman College Center for Drug Discovery, Design & Delivery, Southern Methodist University, Dallas, TX, 75275-0376, United States.
Carolyn K HarrodLaboratory of Molecular Virology, Department of Biological Sciences and the Dedman College Center for Drug Discovery, Design & Delivery, Southern Methodist University, Dallas, TX, 75275-0376, United States.
Brenda Y HernandezHawaii Tumor Registry, University of Hawaii Cancer Center, Honolulu, HI, 96813, United States.
Brooke M EmerlingSanford Burnham Prebys, La Jolla, CA, 92037, United States.
Courtney YatesLaboratory Animal Resource Center, Southern Methodist University, Dallas, TX, 75275, United States.
Robert HarrodLaboratory of Molecular Virology, Department of Biological Sciences and the Dedman College Center for Drug Discovery, Design & Delivery, Southern Methodist University, Dallas, TX, 75275-0376, United States. Electronic address: rharrod@smu.edu.
Southern Methodist University · USSanford Burnham Prebys Medical Discovery Institute · USUniversity of Hawaiʻi at Mānoa · US

Funding

Non-Canonical Phosphatidylinositol Kinases in Triple Negative Breast CancerR01CA237536 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI EMERLING, BROOKE M · 2020 to 2024
$2.2M
Roles of p53-Regulated Pro-Survival Signals in Carcinogenesis by HTLV-1 and High-Risk Subtype HPVsR15CA267892 · NCI · SOUTHERN METHODIST UNIVERSITY · PI HARROD, ROBERT L. · 2023 to 2023
$446k
Coordinate Regulation of p53 and c-Myc in HTLV-1 and HPV-induced CarcinogenesisR15CA202265 · NCI · SOUTHERN METHODIST UNIVERSITY · PI HARROD, ROBERT L. · 2016 to 2016
$437k
NCI NIH HHS R01 CA237536NCI NIH HHS R15 CA202265NCI NIH HHS R15 CA267892
6 · The paper itself

Abstract

The high-risk subtype human papillomaviruses (hrHPVs) infect and oncogenically transform basal epidermal stem cells associated with the development of squamous-cell epithelial cancers. The viral E6 oncoprotein destabilizes the p53 tumor suppressor, inhibits p53 K120-acetylation by the Tat-interacting protein of 60 kDa (TIP60, or Kat5), and prevents p53-dependent apoptosis. Intriguingly, the p53 gene is infrequently mutated in HPV + cervical cancer clinical isolates which suggests a possible paradoxical role for this gatekeeper in viral carcinogenesis. Here, we demonstrate that E6 activates the TP53-induced glycolysis and apoptosis regulator (TIGAR) and protects cells against oncogene-induced oxidative genotoxicity. The E6 oncoprotein induces a Warburg-like stress response and activates PI3K/PI5P4K/AKT-signaling that phosphorylates the TIGAR on serine residues and induces its hypoxia-independent mitochondrial targeting in hrHPV-transformed cells. Primary HPV + cervical cancer tissues contain high levels of TIGAR, p53, and c-Myc and our xenograft studies have further shown that lentiviral-siRNA-knockdown of TIGAR expression inhibits hrHPV-induced tumorigenesis in vivo. These findings suggest the modulation of p53 pro-survival signals and the antioxidant functions of TIGAR could have key ancillary roles during HPV carcinogenesis.

Indexed as

Oncogene Proteins, ViralPapillomavirus InfectionsUterine Cervical NeoplasmsApoptosis Regulatory ProteinsCarcinogenesisFemaleGenes, p53GlycolysisHuman Papillomavirus VirusesHumansHypoxiaTumor Suppressor Protein p53Apoptosis Regulatory ProteinsOncogene Proteins, ViralTumor Suppressor Protein p53c-MycE6 oncoproteinHuman papillomavirusHypoxiaMitochondriap53ROSTIGAR

Identifiers

PMID37257253
PMCPMC10527176
OpenAlexW4377229952

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.